manilatimes16h
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...
AbbVie (ABBV) Q4 2024 Earnings Call Transcript
Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...
Nature17d
Goldie–Coldman and bevacizumab beyond disease progression
Bevacizumab is a recombinant humanized monoclonal antibody that binds VEGF-A and targets tumor associated angiogenesis by preventing receptor binding. Although the precise mechanism of action of ...
Seeking Alpha10d
AbbVie Inc. (ABBV) Q4 2024 Earnings Call Transcript
We have also added depth to our pipeline by signing more than 20 early-stage deals since the beginning of 2024, including promising technologies and innovative mechanisms that can elevate the ...
PipelineReview.com7d
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
NEW YORK, NY, USA I 03, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of ...
Nasdaq19d
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
Phase 1/2 Trial of BOT/BAL With FOLFOX-Bevacizumab in MSS mCRC (Abstract ... Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally ...
PipelineReview.com14d
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK, NY, USA I5, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® ...